Welcome to our dedicated page for Immunocore Holdings plc American news (Ticker: IMCR), a resource for investors and traders seeking the latest updates and insights on Immunocore Holdings plc American stock.
Immunocore Holdings plc reports commercial and clinical developments for a biotechnology issuer whose Nasdaq-listed ADSs represent ordinary shares. The company uses its ImmTAX TCR bispecific immunotherapy platform across oncology, infectious disease and autoimmune programs, with KIMMTRAK (tebentafusp-tebn) approved for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia and the United Kingdom.
Recurring updates cover KIMMTRAK sales and long-term survival data, lifecycle-management studies in uveal and cutaneous melanoma, the PRAME-A02 candidate brenetafusp, earlier ImmTAX candidates, HIV functional-cure research, autoimmune disease pipeline activity, financial results, investor presentations and R&D governance changes.
Immunocore (Nasdaq: IMCR) announced management participation in several investor conferences in September 2026. The Company will host fireside chats at the Cantor Global Healthcare Conference on September 10 at 2:45 p.m. EDT, the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 at 2:35 p.m. EDT, and the Baird 2026 Global Healthcare Conference on September 15 at 12:15 p.m. EDT. Immunocore will also hold 1x1 and small group meetings at the H.C. Wainwright 28th Annual Global Investment Conference on September 16. Presentations will be webcast live with replays available for a limited time via the Investors section of Immunocore’s website.
Immunocore (Nasdaq: IMCR) reported Q2 2026 KIMMTRAK® net revenues of $115.9 million, up 18% year-over-year, with $74.9 million from the US, $34.1 million from Europe and $6.9 million from international markets. According to Immunocore, Q2 2026 net loss narrowed to $0.8 million versus $10.3 million a year earlier, while net income for the first half of 2026 reached $12.2 million compared with a prior-year loss.
R&D expenses rose to $73.9 million and SG&A to $43.9 million in Q2 2026. Cash, cash equivalents and marketable securities were $880.2 million as of June 30, 2026. The company highlighted five-year overall survival data showing KIMMTRAK doubled five-year survival in metastatic uveal melanoma (16% vs 8%; HR 0.67) and reported promising brenetafusp Phase 1/2 data supporting ongoing Phase 3 trials across melanoma and other solid tumors.
Immunocore (Nasdaq: IMCR) will report its second quarter 2026 financial results for the period ended June 30, 2026, on Thursday, August 6, 2026. The company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) to discuss results and provide a business and portfolio update.
The audio webcast can be accessed via the ‘Events and Presentations’ section of Immunocore’s investor website, with a replay available for a limited time. Conference call dial-in numbers are 877-405-1239 (domestic, toll-free) and +1 201-389-0851 (international, toll).
Immunocore (Nasdaq: IMCR) reported updated Phase 1/2 data for brenetafusp in heavily pretreated HLA-A*02:01-positive advanced melanoma. Monotherapy showed median overall survival of 14.3 months, with 6- and 12-month survival of 87% and 57%, disease control rate 52% and overall response rate 12%.
Clinical benefit was observed in primary PD-1–resistant patients (median OS 14.7 months) and supported selection of a 160 mcg dose for the Phase 3 PRISM-MEL-301 first-line trial with nivolumab. Combination with pembrolizumab in 10 patients showed numerically higher response and disease control. Brenetafusp was generally tolerated; key treatment-related adverse events included mainly low-grade CRS (56%), rash (44%) and transient Grade 3-4 lymphocyte decrease (25%). A second ASCO 2026 poster suggested IL7 may enhance ImmTAC T cell activity in vitro and in vivo.
Immunocore (Nasdaq: IMCR) reported Q1 2026 results: KIMMTRAK net sales $106.7M (13.6% YoY) and cash, cash equivalents and marketable securities $844.9M. The company presented five-year Phase 3 OS data showing a doubling of 5-year survival (16% vs 8%; HR 0.67) and median OS 21.6 vs 16.9 months. Pipeline updates include ongoing Phase 3 trials (TEBE-AM, PRISM-MEL-301), registrational timelines in 2026, and multiple Phase 1/2 programs with data expected in H2 2026.
Immunocore (Nasdaq: IMCR) reported five-year overall survival (OS) improvements with KIMMTRAK in first-line HLA-A*02:01+ metastatic uveal melanoma patients.
KIMMTRAK achieved 5-year OS of 16% vs 8% for control (HR 0.67, 95% CI 0.54-0.85); median OS was 21.6 vs 16.9 months. Results were consistent across high tumor burden, elevated LDH, and extrahepatic disease. ctDNA clearance correlated with longer survival.
Immunocore (Nasdaq: IMCR) will present at the 25th Annual Needham Virtual Healthcare Conference with a fireside chat on April 13, 2026 at 3:00 p.m. EDT. The presentation will be webcast live and a replay will be available for a limited time via the company website.
Immunocore (Nasdaq: IMCR) will present the five-year overall survival (OS) results from the KIMMTRAK (tebentafusp-tebn) Phase 3 trial in previously untreated HLA-A*02:01 positive metastatic uveal melanoma at AACR 2026.
The oral presentation is scheduled for Sunday, 19 April 2026, 3:00–5:00 p.m. PT; a company release will follow with the full five-year OS data and additional analyses including subsequent treatments, treatment beyond progression, and prognostic factors.
Immunocore (Nasdaq: IMCR) announced management will present at multiple investor conferences in March 2026, including TD Cowen (Mar 3), Leerink (Mar 9), Barclays (Mar 10), UBS Biotech Summit (Mar 10) and Jefferies Biotech on the Beach (Mar 11).
Where relevant, presentations will be webcast live via the company’s Investors > Events & Presentations page, with replays available for a limited time.
Immunocore (Nasdaq: IMCR) reported KIMMTRAK net sales of $104.5M in Q4 2025 and $400.0M for FY2025, cash and marketable securities of $864.2M, R&D spend of $274.9M, and a FY net loss of $35.5M.
The company expects TEBE-AM enrollment to complete in 1H 2026 with topline OS data as early as 2H 2026, PRAME and HIV data in 2H 2026, and an autoimmune Phase 1 start in 1H 2026.